US-based bioscience tool provider BioLife Solutions has formed a co-investment accelerator with healthcare investment firm Casdin Capital to back early-stage cell and gene therapy bioproduction instrument developers.
The formation of the initiative came alongside dual $1m convertible note investments in viral vector manufacturing technology developer iVexSol.
BioLife and Casdin said they are also set to each invest $1.5m in Sexton Biotechnologies, a bioproduction tool developer spun off from incubator Cook Regentec, taking an 18% stake each as part of a $5m round that includes Cook Regentec and BioCrossroads Indiana Seed Fund III.
Mike Rice, chief executive of BioLife, said: “We are committed to leveraging technology to accelerate therapeutic innovation. Our strategic investment program enables early-stage companies developing disruptive tools to access financial support, distribution and operational leadership.”
